Arcus Biosciences Inc

In Stage 2 Advancing, RCUS maintains higher highs and higher lows above its rising 50-day SMA, reflecting a bullish medium-term bias within a long-term uptrend. However, a Bearish Pivot Point and failure to reclaim the 9- and 20-day EMAs have turned short-term momentum negative. Execution should be deferred until price shows constructive pullback absorption at the 50-day SMA or a clear reclaim of the short-term EMAs.

• ↑Casdatafan achieves 45% ORR vs Belzutifan’s 22.5% and 15.1-month median PFS
• ↑Cash reserves of ~$1B at Q2 2024 fund operations into mid-2027
• ↓Negative profitability and earnings yield reflect weak return generation